Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Linde A Miles, PhD, Robert L Bowman, PhD, Tiffany R Merlinsky, Aik Ooi, PhD, Pedro Mendez, Christopher Famulare, MS, Minal A Patel, MPH, Kelly Bolton, MD PhD, Neil Palmisiano, MD MS, Martin P. Carroll, MD, Elli Papaemmanuil, PhD, Ahmet Zehir, PhD, Sara E. Meyer, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD

Blood (2019) 134 (Supplement_1): 913.

https://doi.org/10.1182/blood-2019-128763

Published: 2019

Journal Articles

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD MS, Margaret Kasner, MDMSc

Blood (2019) 134 (Supplement_1): 2597.

https://doi.org/10.1182/blood-2019-131979

Published: 2019

Journal Articles

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, William O'Hara, PharmD, John L Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 4661.

https://doi.org/10.1182/blood-2018-99-110815

Published: 2018

Journal Articles

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

Fangxin Hong, PhD, Gita Thanarajasingam, MD, Stephen M. Ansell, MD PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisiano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Thomas E. Witzig, MD, Amylou C. Dueck, PhD, Paul Novotny, Brad S Kahl, MD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 623.

https://doi.org/10.1182/blood-2018-99-119372

Published: 2018

Journal Articles

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD, Pierluigi Porcu, MD, William O'Hara, PharmD, John L Wagner, MD, Neal Flomenberg, MD

Blood (2018) 132 (Supplement 1): 3371.

https://doi.org/10.1182/blood-2018-99-117364

Published: 2018

Journal Articles

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Jason Chen, MD, Jonathan Pan, MD, John L. Wagner, MD, Michael Sun, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Neil Palmisiano, MD, Ubaldo Martinez-Outschoorn, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Dolores Grosso, DNP, CRNP

Blood (2017) 130 (Supplement 1): 3200.

https://doi.org/10.1182/blood.V130.Suppl_1.3200.3200

Published: 2017

Journal Articles

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

Dolores Grosso, DNP, CRNP, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Margaret Kasner, MD, Thomas Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, William O'Hara, PharmD, Neil Palmisiano, MD, John L. Wagner, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD

Blood (2017) 130 (Supplement 1): 1959.

https://doi.org/10.1182/blood.V130.Suppl_1.1959.1959

Published: 2017

Journal Articles

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

Neil Palmisiano, MD, Grace Jeschke, PhD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 3858.

https://doi.org/10.1182/blood.V130.Suppl_1.3858.3858

Published: 2017

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

NARROW

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

HSCT Engraftment Kinetics: Differences in Chimerism between Haploidentical (HI) and Matched Related (MR) Transplant Recipients (HSCT) after the 2 Step Approach

Differences in Allogeneic Product T-Cell Subsets According to Donor Age: Associations with Immune Reconstitution and Acute Graft Versus Host Disease (aGVHD) in Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

The Presence of Recipient CMV Immunodominant Human Leukocyte Antigen (HLA) Alleles Affect Outcomes after Haploidentical (HI) Hematopoietic Stem Cell Transplantation (HSCT)

A Phase II Trial of Sirolimus with Standard Induction Chemotherapy in Patients with De Novo Acute Myeloid Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only